ABCureD was the standout winner of the NBG Business Seeds 13th Innovation & Technology Competition for its groundbreaking invention in diabetes management.
The National Bank of Greece event is the longest-running innovation competition in Greece that not only celebrates but also actively supports innovative startups and entrepreneurs. With over 7.000 participants across the years, it has nurtured visionary ideas and technological advancement.
ABCureD PC is a spin-off biotechnology company of Democritus University of Thrace that uses AI in novel ways to accelerate and optimize health solutions. It created a revolutionary minimally invasive method – the only one of its kind internationally – for diagnosing prediabetes and predicting and monitoring Type 2 Diabetes Mellitus. Their diagnostic method has the highest reported levels of sensitivity and accuracy in detecting pathological manifestations of T2DM. This is a game-changing technology in the healthcare industry, reshaping our approach to this chronic condition.
Central to ABCureD’s success is its pioneering use of Artificial Intelligence. Their diagnostic kit leverages machine learning to predict future health statuses with astonishing precision. This fusion of technology and medicine holds the promise of transforming how we monitor and manage health conditions.
The NBG Business Seeds award was accompanied by a monetary prize of 20k euros. Dr. Ekaterini Alexiou-Chatzaki, Professor of Pharmacology at the Democritus University of Thrace, accepted the award on behalf of the company.
Yet another distinction for ABCureD after being recently awarded the 1st prize at the 3rd Health Innovation Forum of the Hellenic Health Bio Cluster (HBio), competing with the most significant Greek and European startups from the Health sector.